Imiphumela emibi ye-Asacol (i-Oral Mesalamine, i-Pentasa, i-Mesasal, i-Salofalk)

Imiphumela Engahle Yenzeke Yeli Klasi Elijwayele Ukusetshenziswa Imithi

Yini i-Asacol?

I-Asacol (mesalamine) iyi-5-aminosalicylic acid (5-ASA) eyadluliswa ngo-Agasti 1997 yokwelashwa kwe-ulcerative colitis. I-Asacol isebenza ngokuyinhloko emathunjini, igxilise ukuvuvukala okubangelwa i-ulcerative colitis, okuyisinye sezimo eziyinhloko zesifo sofuba esiswini (IBD) . I-Asacol ngaphambili yayibuye isetshenziselwe ukuphatha olunye uhlobo lwe-IBD, isifo sikaCrohn.

Kodwa-ke, kusukela ngaleso sikhathi kuye kwacwaningwa ngokujulile futhi ochwepheshe be-IBD manje bakholelwa ukuthi i-mesalamine ayiphumeli kakhulu ekunakekeleni isifo sikaCrohn, futhi akusasetshenziselwa ukusetshenziswa kwendlela yokuphatha le ndlela ye-IBD.

I-Asacol iyiDakamizwa Yokulondoloza

I-Asacol ihlukaniswa "izidakamizwa" izidakamizwa, okusho ukuthi inikezwa isikhathi eside ukuphatha ukwelashwa kwesilonda. I-ulcerative colitis ibangela ukuvuvukala ekoloni, phakathi kwezinye izimpawu nezimpawu kuwo wonke umzimba. I-Asacol isetshenziselwa ukusiza ukuyeka ukuvuvukala ekoloni ekhona, futhi ngokuvamile iqala ukusebenza emasontweni angaba ngu-3. Ngemuva kokuthi ukuvuvukala kungaphansi kokulawula, iziguli zibekwe lo muthi ukusiza ukuvimbela ukuqhuma okuningi kwesifo kungenzeki.

Lesi sidakamizwa sesondlo siyaziwa ukuthi sinemiphumela emibi kakhulu, kodwa ezinye zisasebenza. Ukulandela uhlu lwemiphumela emibi kanye nemiphumela emibi ye-Asacol.

Imiphumela Ejwayelekile Ejwayelekile

Hlola nodokotela wakho uma ngabe yimiphi imiphumela emibi elandelayo iqhubeka noma ihlupha:

Okuncane Okuvamile noma Okuvamile

Hlola nodokotela wakho uma ngabe yimiphi imiphumela emibi elandelayo iqhubeka noma ihlupha:

Yazisa njalo uDokotela

Okungajwayelekile

Akuvamile

Izimpawu Zokudlula isikhathi

Izixwayiso Nge-Asacol

I-Asacol ibhekwa njengokuphephile, kodwa ihlotshaniswa nezinye izenzakalo ezimbi ukuthi abantu abathatha lesi sidakamizwa kufanele bazi. Abanye abantu baye bahlakulela izinkinga nezinso zabo, futhi kunconywa ukuthi abantu abathatha lesi sidakamizwa banomsebenzi wabo wezinso ezihlolwe njalo njalo.

Abanye abantu baye babhekana nezinkinga ezilinganisa izimpawu zesifo se-ulcerative colitis, esihlanganisa isifo sohudo, ubuhlungu bekhanda kanye nobuhlungu besisu. Ukuphendula okwenziwe nge-allergenic nakho kungenzeka, futhi udokotela kufanele axoxe nganoma yikuphi ukubhekana nokugula okwenziwe ngaphambili kwe-mesalamine noma i- sulfasalazine .

Okubalulekile

I-Asacol ivame ukubekezelela kakhulu abantu abaningi, futhi ngokuvamile isetshenziswa isikhathi eside yilabo abane-ulcerative colitis. Kodwa-ke, njenganoma imuphi umuthi, kukhona amandla okuba nemiphumela emibi nemiphumela emibi. Kubantu abaningi imiphumela emibi iyamnene, kodwa abantu abathatha i-Asacol kumele baqaphele ukuthi kungenzeka yini ukuthi bangabe besabela kanjani, kube nomthelela omubi ezinso, noma kube nokudlulela kwesifo sohudo kanye nobuhlungu besisu. Kunoma ikuphi ukukhathazeka ngemiphumela emibi ka-Asacol, xhumana nodokotela wakho.

Ezinye imiphumela emibi engabhalwanga ngenhla zingase zenzeke kwezinye iziguli. Uma ubona noma yimiphi imiphumela, hlola nodokotela wakho. Lolu lwazi luqondiswa kuphela njengeseluleko - njalo uxoxe nodokotela noma wemithi ukuze uthole ulwazi oluphelele mayelana nemithi yokwelashwa.

Umthombo:

> I-Actavis Pharma, Inc. "Amaphilisi e-ASACOLĀ® HD (mesalamine) okulibala ukulibala, okusetshenziselwa ngomlomo Ukwamukelwa kokuqala kwe-US: 1987." pi.actavis.com.

ULichtenstein GR, Hanauer SB, uSandborn WJ; I-Practice Parameters Committee ye-American College of Gastroenterology. "Ukuphathwa kwesifo sikaCrohn kubantu abadala." Am J Gastroenterol. 2009 Feb; 104 (2): 465-83; Imibuzo 464, 484.